Generative AI: a generation-defining shift for biopharma regulatory affairs
J
Jon Williams
D
Donna Boyce
G
Graziella Collu
S
Sean Curtis
R
Ramzi Dagher
P
Peter Gamble
M
Magdalena Jayatissa
E
Eugene Leypunskiy
S
Sabine Luik
B
Beatriz Monedero Alvarez
T
Trine Birgitte Moulvad
M
Meena Murugappan
A
Alexandra Pearce
E
Eddie Reilly
P
Piero Rijli
R
Ruben Rizzi
K
Katrin Rupalla
P
Punam Sandhu
T
Thomas Seck
M
Michael Søberg Christensen
M
Mark Taisey
C
Cyril Widmaier
M
Myrto Lee
Article Details
Journal
Nature Reviews Drug Discovery
Volume / Issue
Vol. 24, Issue 9
Published
September 01, 2025
Pages
651-652
ISSN
1474-1776
Publisher
Springer Science and Business Media LLC
Journal Info
Nature Reviews Drug Discovery
Springer Science and Business Media LLC
ISSN: 1474-1776 Q1 Medicine
Authors (23)
J
Jon Williams
D
Donna Boyce
G
Graziella Collu
S
Sean Curtis
R
Ramzi Dagher
P
Peter Gamble
M
Magdalena Jayatissa
E
Eugene Leypunskiy
S
Sabine Luik
B
Beatriz Monedero Alvarez
T
Trine Birgitte Moulvad
M
Meena Murugappan
A
Alexandra Pearce
E
Eddie Reilly
P
Piero Rijli
R
Ruben Rizzi
K
Katrin Rupalla
P
Punam Sandhu
T
Thomas Seck
M
Michael Søberg Christensen
M
Mark Taisey
C
Cyril Widmaier
M
Myrto Lee
Related Articles from this Journal
Can multispecific biologics break the efficacy ceiling?
Asher Mullard
Jul 2026
10.1038/d41573-026-00106-5
Novel drug targets in 2025
Sorin Avram, Liliana Halip et al.
Jul 2026
10.1038/d41573-026-00102-9
The unglamourous AI wins that are quietly transforming drug discovery and development
Asher Mullard
Jul 2026
10.1038/d41573-026-00099-1
Upcoming FDA approval decisions in Q3 2026
Swetha Kota
Jul 2026
10.1038/d41573-026-00103-8
Antiviral peptide nabs FDA approval for hepatitis delta virus infection
Asher Mullard
Jul 2026
10.1038/d41573-026-00101-w